Full-Time

Warehouse Specialist

Shift Position

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Mid

Melbourne VIC, Australia

This position is site-based, requiring you to be at Moderna’s site full-time. This position is not eligible for remote work.

Category
Warehouse Operations
Operations & Logistics
Required Skills
Supply Chain Management
Inventory Management
SAP Products
Requirements
  • High School diploma, with at least 2 years of experience in Warehouse Operations and Shipping; BS/BA Degree preferred.
  • This position is site-based, requiring you to be at Moderna’s site full-time. This position is not eligible for remote work.
Responsibilities
  • Independently coordinating deliveries to internal customers and conducting daily SAP transactions.
  • Conducting daily cycle counts and overseeing the wipe-down activities for materials as they enter manufacturing suites.
  • Efficiently managing the segregation of expired materials and ensuring accurate, up-to-date inventory records within SAP.
  • Executing comprehensive warehouse operations to fully support manufacturing teams.
  • Leading and participating in initiatives to enhance warehouse operations, with a focus on safety, compliance, and operational efficiency.
  • Collaborating closely with the warehouse operations lead and the global supply chain team to optimize processes and contribute to overall supply chain effectiveness.
  • Performing additional duties as needed to support our high-growth environment and transformational objectives.
Desired Qualifications
  • Experience in a highly regulated industry, Pharmaceutical, or related field.
  • Ability to lift and move products.
  • Proficient use of Microsoft Office (SAP, Smartsheet, Microsoft Word, and Excel).
  • Outstanding communication skills (verbal and written) in English and French.
  • Collaborative, and customer-focused attitude.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for biological functions. Their products work by delivering mRNA into the body, which instructs cells to create specific proteins that can help prevent or treat diseases. This approach is different from traditional medicines, as it leverages the body's own cellular machinery to generate therapeutic proteins. Moderna's goal is to create a new category of medicines that can significantly enhance patient care and improve health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna expects 10 product approvals by 2027, boosting its market presence.
  • The company secured a tender for mRNA COVID-19 vaccines in the EU.
  • Moderna is exploring mRNA for non-infectious diseases, expanding its therapeutic scope.

What critics are saying

  • Moderna faces a patent lawsuit with Pfizer and BioNTech over mRNA technology.
  • Emerging competition from companies like CureVac threatens Moderna's market share.
  • Public skepticism towards mRNA technology could impact vaccine acceptance.

What makes Moderna unique

  • Moderna is pioneering mRNA technology as a new class of medicines.
  • The company is developing a personalized cancer vaccine with Merck, launching in 2027.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
PharmiWeb
Mar 28th, 2025
Moderna Receives Medicines And Healthcare Products Regulatory Agency Marketing Authorization In The Uk For Rsv Vaccine

mRESVIA® is Moderna's second approved product in the UKCAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older."The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year."RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. In the UK, RSV has an impact on elderly adults and is responsible for 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths in adults 65 years of age and older per year.[i]"Given the serious consequences of RSV for older people, which can lead to hospitalization and severe outcomes, we are delighted that the MHRA has authorized our RSV vaccine," said Darius Hughes, UK General Manager of Moderna. "With the MHRA decision, mRESVIA becomes Moderna's second approved product in the UK, further demonstrating the role of mRNA vaccines in helping to protect the public from respiratory diseases."The approval is based on positive data from the Phase 3 clinical trial ConquerRSV , a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries. No serious safety concerns were identified in the Phase 3 trial.About mRNA-1345 (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein

Assure Test
Mar 7th, 2025
Pfizer & BioNTech vs. Moderna: COVID-19 Vaccine Patent Lawsuit

The high-profile lawsuit between Pfizer, BioNTech, and Moderna over mRNA COVID-19 vaccine patents remains one of the most closely watched cases in 2025.

Bloomberg
Mar 5th, 2025
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck

Moderna Inc. expects to launch a personalized cancer vaccine that it's developing with Merck & Co. by 2027, one of its top executives said.

The Wall Street Journal
Feb 27th, 2025
Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract

Moderna was awarded the contract from the U.S. Department of Health and Human Services in January during the Biden administration to accelerate development of its mRNA-based vaccine, and as part of an effort to address growing concerns of a bird flu pandemic in humans.

Financial Modeling Prep
Feb 14th, 2025
Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector

Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.